Loading...
•
Mar 31, 2020
Bicycle Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020 and discussed recent corporate updates.
Key Takeaways
Bicycle Therapeutics reported its Q1 2020 financial results, highlighting two new immuno-oncology collaborations, including a partnership with Genentech worth up to $1.7 billion. Key milestones were reached in clinical programs, such as establishing a recommended Phase II dose for BT1718 and advancing BT5528 through Phase I dose escalation.
Entered two new immuno-oncology collaborations, including a partnership with Genentech worth up to $1.7 billion.
Established a recommended Phase II dose for BT1718.
Advanced BT5528 through the Phase I dose escalation quickly.
Welcomed Zafar Qadir as General Counsel.
Forward Guidance
Despite uncertainties associated with the COVID-19 pandemic, Bicycle Therapeutics remains focused on achieving its stated goals for the year as planned and looks forward to providing updates on its progress as it advances its novel therapeutic candidates into and through the clinic.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...